City
Epaper

Pfizer to send 50 million COVID-19 vaccines to India with conditions

By ANI | Updated: May 26, 2021 20:55 IST

US pharmaceutical giant Pfizer is likely to supply 50 million COVID-19 vaccines to India in 2021, albeit with a few conditions, sources told ANI on Wednesday.

Open in App

US pharmaceutical giant Pfizer is likely to supply 50 million COVID-19 vaccines to India in 2021, albeit with a few conditions, sources toldon Wednesday.

However, the drugmaker has asked for relaxations in some clauses, including indemnification for its shots, sources informed.

Meanwhile, Moderna, another pharmaceutical giant in the US, sources said is expecting to start manufacturing its COVID-19 vaccines in India following an analysis with Cipla, a pharmaceutical company based in Mumbai, among other Indian firms.

Earlier, both drugmakers had allegedly refused to send vaccines directly to the state governments of Delhi and Punjab, claiming that they will only deal with the Central government.

"We have spoken to Pfizer and Moderna for vaccines, and both the companies have refused to sell vaccines directly to us. They have said that they will deal with the Government of India alone," Delhi Chief Minister Arvind Kejriwal had said on Monday.

India is moving towards vaccine sufficiency as inoculations with the Russian vaccine Sputnik V began in the country earlier this month.

Sources toldthat India and Russia are planning to manufacture around 35-40 million doses every month that will start from August or September.

Before the transfer of technology in August for local production, Russia will send close to 18 million Sputnik V doses to India - 3 million in May, 5 million in June and 10 million in July, said sources.

On May 24, the Russian Direct Investment Fund (RDIF) and Panacea Biotec, one of the leading pharmaceutical producers in India, had launched the production of the Sputnik V COVID-19 vaccine.

Other sites of production of the Sputnik V vaccines are - Hetero Biologics, Virchow Biotech, Gland Pharma, Stelis Biopharma and Shilpa Medicare.

India has also been using two vaccines - Covishield by the Serum Institute of India (SII) and Covaxin by the Hyderabad-based Bharat Biotech. According to the sources, India is expected to produce approximately 20-25 crore vaccines per month.

Sources informed that two next-generation vaccines will also be made in India. One is the DNA vaccine by Cadila Zydus and the other is an mRNA vaccine by Gennova Biopharmaceuticals Ltd. Both vaccines have shown promise and are expected to reduce international dependence for the supply of doses.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Stelis Biopharma Private LimiteddelhimumbaiArvind KejriwalCipla limitedPfizer`delhiCiplaDelhi capitalSouth delhi district administration
Open in App

Related Stories

Navi MumbaiMumbai: BMC Fines Contractor, Quality Agency ₹75 Lakh for Poor Roadwork

MumbaiCelebrating 65 Years of Maharashtra: Mumbai's Role in Shaping the State's Identity

NationalLPG Cylinder Price Cut From May 1: 19-Kg Commercial Gas Cylinder Becomes Cheaper by Rs 17, Check Rates in Mumbai, Kolkata

NationalDilli Haat Fire: Massive Blaze Erupts at Delhi's Popular Market, 26 Shops Gutted (Watch Video)

MumbaiMumbai: Gold Sales Cross ₹12,000 Crores Nationwide on Akshaya Tritiya; Mumbai MMR Sees ₹800 Crores Trade

International Realted Stories

InternationalEAM Jaishankar highlights role of innovation, technology in building Viksit Bharat at WAVES 2025

InternationalAngolan President Joao Manuel Goncalves Lourenco arrives in New Delhi

International"I don't think it is a secret that Pakistan has a past": Bilawal Bhutto admits Pakistan's ties to terror organisations

InternationalS. Korea reaffirms vigilant monitoring of financial markets amid political turmoil

InternationalUS approves USD 131 million military sale to boost India's maritime security in Indo-Pacific